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ABSTRACT 
The synthesis of hybrid urea-based foldamers containing isosteric guanidinium linkages at selected 
positions in the sequence is described. We used a post-elongation approach whereby the 
guanidinium moiety is introduced by direct transformation of a parent oligo(urea/thiourea) foldamer 
precursor. The method involves activation of the thiourea by treatment with methyl iodide and 
subsequent reaction with amines. To avoid undesired cyclization with the preceding urea moiety 
resulting in heterocyclic guanidinium formation in the main chain, the urea unit preceding the 
thiourea unit in the sequence was replaced by an isoatomic and isostructural γ-amino acid. The 
approach was extended to solid-phase techniques to accelerate the synthesis of longer and more 
functionalized sequences. Under optimized conditions an 8-mer hybrid oligomer incorporating a 
central guanidinium linkage was obtained in good overall yield and purity. This work also reports 
data related to the structural consequences of urea by guanidinium replacements in solution and 
reveals that helical folding is substantially reduced in oligomers containing a guanidinium group.  
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INTRODUCTION 
Aliphatic N,N’-linked oligoureas1 are a class of peptidomimetic oligomers which adopt a regular 
helical conformation stabilized by a network of H-bonds closing 12 and 14-membered 
pseudorings.
2
 These non-peptide α-helicomimetic foldamers3 possess specific advantages for 
possible (bio)applications, such as high folding fidelity and stability to enzymatic proteolysis.
4
 
Oligoureas do share high sequence modularity and synthetic accessibility with synthetic peptides.
5
 
Variation of substitution patterns and the introduction of isosteric backbone modifications are two 
complementary approaches to generate different spacing and projection of side chains at the surface 
and fine tune the properties of the helix. We have previously reported heterogeneous urea-based 
backbones containing various proportion of urea bond surrogates including amide (A), carbamate 
(C),
6,7
 and thiourea (T)
8
 units and have shown that the folding propensity can be controlled by the 
ratio between urea (U) and isosteric units and by their relative distribution in the sequence (Figure 
1a). 
To further modulate the molecular recognition and biological properties of oligourea helices, we 
have now considered the replacement of the neutral urea linkage by a guanidinium (G) unit at 
selected positions in the sequence (Figure 1b). The guanidinium moiety is protonated over a wide 
range of pH and displays many useful features for molecular recognition in competitive solvents, 
serving as H-bond donor, charge pairing agent and being capable of cation- π-stacking interactions. 
It is a major functional group in proteins and natural products,
9
 a useful pharmacophore in 
medicinal chemistry and its physicochemical properties have been largely exploited in 
supramolecular chemistry for the design of anion receptors and sensors,
10-13
 and in 
organocatalysis.
14
 Guanidinium-rich molecules ranging from peptides to dendrimers and artificial 
oligomers efficiently enter living cells and have been widely explored as molecular transporters.
15-20
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Figure 1. a) Urea-based unit in aliphatic N,N’-linked oligoureas and corresponding A, C, G, and T 
units as urea bond surrogates; b) Schematic representation of the polar helical conformation of 
oligo(thio)urea foldamers and illustration of the thiourea  guanidinium replacement.  
 
Oligomeric guanidines, i.e. backbones with N,N’-bridged guanidine units have also attracted 
interest as ligands of protein surfaces
21
 and as abiotic folded systems.
22
 For example, aromatic 
oligomeric N,N’-dimethyl-N,N’-diphenyl guanidines have been reported to fold into well- defined 
layered structures akin to that of corresponding aromatic oligoureas. Aliphatic oligomers with 
guanidinium backbones have also been developed as oligonucleotide
23-26
 and peptide
27,28
 mimics. 
Several solid-phase synthesis approaches to access aliphatic oligomeric guanidines have been 
reported and the most effective methods are based on the use of arylsulfonyl (e.g. Pbf: 2,2,4,6,7-
Pentamethyldihydrobenzofuran-5-sulfonyl), and alkoxycarbonyl (e.g. Fmoc: 9-
fluorenylmethyloxycarbonyl, Cbz: carbobenzoxyl and Troc: trichloroethoxycarbonyl) activated 
thiourea monomers.
27,29-31
 In these studies, the guanidylation reaction generally involves the 
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transformation of the thiourea moiety into a carbodiimide by treatment with EDC, Mukaiyama 
reagent or HgCl2 in the presence of TEA and subsequent reaction with the terminal amine of the 
growing chain.
32
 This general approach and the use of N-((2-azidoalkyl)-Pbf-thioureas
27
 as 
activated monomers are compatible with the solid-phase synthesis of aliphatic N,N’-linked 
oligourea foldamers on TFA-sensitive resins
5
 and well-suited for the preparation of cognate 
urea/guanidine hybrid oligomers. Yet, this approach requests the preparation of specific activated-
thiourea building blocks and the preparation of highly labile arylsulfonyl isothiocyanate and we 
were more interested by the possibility to introduce the guanidinium moiety at a later stage in the 
synthesis by using urea/thiourea hybrid foldamers
8
 as advanced intermediates (Figure 1b). 
Following exploration of reaction conditions and optimization in solution using model oligomers, 
we have extended the approach to solid-phase synthesis and applied it to a longer oligomer carrying 
multiple functionalized side chains. In this work, we also report 
1
H-NMR and CD (circular 
dichroism) data about the conformational preferences of the resulting urea/guanidinium (U/G) 
hybrids in direct comparison with the cognate urea/thiourea (U/T) and urea oligomers. 
 
RESULTS AND DISCUSSION 
Guanidinylation reaction of urea/thiourea hybrid oligomers in solution. Short-chain N-tert-
butyloxycarbonyl protected dimer 1a and tetramer 2a were initially selected as model urea/thiourea 
hybrid oligomers (TU and UUTU sequences, respectively) to test the best conditions to transform 
the thiourea linkage into the corresponding guanidinium. The oligomers were synthesized in 
solution using activated building blocks BB1 and BB2 as described previously (Figure 2 and see 
general procedure for details).
8,33
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Figure 2. Sequences of target (thio)urea-based hybrid oligomers 1-4 for investigating 
guanidinylation reaction in solution. Formulae of activated building blocks BB1 and BB2 used to 
prepare oligomers 1, 2 and 4. Oligomer 3 was described previously.
8
 
 
We performed the guanidinylation reaction by a two-step strategy (Rathke synthesis
34
) involving 
the S-methylation of the thiourea linkage by reaction with iodomethane (CH3I) to form the S-
methylthiouronium iodide salt followed by a direct nucleophilic substitution in presence of the 
desired amine (Scheme 1).
35
 Initial efforts were dedicated to the formation of N,N’-disubstituted 
guanidinium derivatives 5 (Scheme 1a). Dimer 1a was thus first S-methylated with CH3I to form 
intermediate 6 and subsequent substitution reaction was carried out in 7.0 N ammonia in CH3OH as 
reaction medium with heating at 40-45 °C during the whole reaction process. The progress of the 
reaction was monitored by reversed phase HPLC (RP-HPLC) and showed complete disappearance 
of dimer 1a. However, RP-HPLC analysis of the crude product after reaction workup revealed the 
presence of two main products in a ratio of 33:67 that were subsequently isolated by silica gel 
chromatography. After careful structural characterization, it appeared that under such conditions the 
major product was the cyclic N,N',N"-guanidine derivative 7 (Scheme 1a, Table 1 and see 
supporting information for detailed characterization). A similar ratio of both the expected guanidine 
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derivative 8 and the corresponding cyclic guanidine 9 as the main product was obtained when the 
reaction conditions were applied to tetramer 2a (Scheme 1b, Table 1 and see supporting 
information). At this stage, we assumed that the heterocyclic guanidine products formed because 
the N' nitrogen of the neighbouring urea moiety was sufficiently nucleophilic in basic conditions to 
quickly react with the newly formed S-methylthiouronium intermediate. This hypothesis was further 
confirmed by reacting S-methylthiouronium 10 with DIPEA as base in pure MeOH (Scheme 1b). 
After 24 h, there was no more trace of 10 in the reaction mixture and cyclic guanidine 9 was 
observed as the main product (see supporting information for details).  
 
Scheme 1. Synthesis of N,N’-disubstituted  and N,N’,N”-trisubstituted guanidinium oligomers from 
oligo(thio)urea oligomers 1a , 2a and 3. 
 
A similar outcome was observed when attempting to prepare the corresponding N"-substituted 
guanidine derivatives with n-propylamine as the nucleophile. The cyclic guanidine 9 was obtained 
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as the major product when starting from tetramer 2a in MeOH (Table 1, entry 3). The influence of 
the nature of the solvent on this guanidinylation reaction was next evaluated and we found that the 
ratio between cyclic and linear products could be reversed in pure acetonitrile. Under these 
conditions, the desired linear N,N',N’’-trisubstituted guanidinium compound 11 was formed as the 
main product (Scheme 1b, Table 1, entry 4). However, the reaction in acetonitrile was much slower 
than in methanol and required larger excess of the primary amine to convert the starting thiourea 
into the N,N',N’’-trisubstituted guanidinium derivative. This guanidinylation reaction in acetonitrile 
was repeated with a 0.5M ammonia solution in 1,4-dioxane. The expected linear N,N’-disubtituted 
guanidinium compound 8 was obtained as the main compound (Table 1, entry 5), which confirms 
the strong influence of the solvent on the outcome of the reaction. The linear to cyclic product ratio 
was further improved by using THF as a co-solvent (Table 1, entry 6). These conditions were 
finally applied to known hexamer 3
8
 (scheme 1c) and the corresponding linear guanidinium 
derivative 12 was obtained together with the cyclized product 13 with a 75:25 ratio (Table 1, entry 
7). 
 
Table 1. Outcome of the guanidinylation reaction on oligo(thio)ureas 1a, 2a and 3 
entry substrate nucleophile  
equiv. of 
amine 
(co)solventa time (h) ratio linear:cyclic productb 
1 1a 7N NH3
 
 ~ 150 CH3OH 48 33:67 (5:7) 
2 2a 7N NH3 ~ 300 CH3OH 24 26:74 (8:9) 
3 2a n-PrNH2  20
 
 CH3OH 24 15:85 (11:9) 
4 2a n-PrNH2 45
 c
 CH3CN 120 73:27 (11:9) 
5 2a 
0.5M NH3 
in 1,4-dioxane 45
c
 CH3CN 120 85:15 (8:9) 
6 2a 
0.5M NH3 
in 1,4-dioxane 
45
c
 THF 38 97:3 (8:9) 
7 3 
0.5M NH3 
in 1,4-dioxane 
60
c
 THF 150 75:25 (12:13) 
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a
The reaction was carried out at 40-45°C; 
b
Determined by RP-HPLC analysis; 
c
The amine was added in several 
portions depending on the progress of the reaction. 
Guanidinylation of γ-amino acid-containing oligo(thio)urea substrates. In order to avoid possible 
intramolecular cyclization leading to the incorporation of a heterocyclic guanidine in the foldamer 
backbone, (Scheme 1), we thought to substitute the urea residue (U unit) preceding the thiourea 
moiety by the corresponding γ4-amino acid derivative (A unit). Indeed, U and A units are 
isostructural and it has been shown previously that oligo(urea/γ-amide) hybrids display similar 
helical folding propensities compared to homooligoureas.
6
 The corresponding dimer 1b and 
tetramer 2b equipped with thiourea and amide linkages (TA and UUTA sequences, respectively) 
were synthesized in solution according to previously reported procedures.
6,8
 
 
Figure 3. Crystal structures of (a) -residue-containing oligo(thio)urea 2b, (b) hexamer 4, and (c) 
structural alignment of the crystal structures of the hexamer 4 (light grey) with a cognate urea 6-mer 
(U6)
8
 (slate blue), the side-chains have been omitted for clarity reasons, calculated RMSD = 0.150 
Å. Only one of the two independent molecules present in the asymmetric unit of the crystal of 4 is 
represented.  
X-ray diffraction analyses of single crystals of 4-mer hybrid 2b provided detailed information on 
the structural consequences of the local U  A replacement in 2. As shown in Figure 3a, the 
structure of 4-mer 2b is helical and compares well with the canonical 2.5-helical structure reported 
for the cognate U4 homooligourea foldamer.
7
 Root-mean square deviations (RMSDs) calculated for 
the backbone asymmetric C atoms (CH(R)) of the two molecules highlights the correlation between 
10 
 
the two structures (RMSD for residues 1–4 = 0.129 Å). It is noteworthy that the intramolecular H-
bond network is maintained with the thiocarbonyl group pointing towards the negative pole of the 
helix macrodipole similar to what was observed in longer helical oligo(thio)urea hybrids. These 
results provide further evidence that the combination of a -amino acid residue and a thiourea unit 
(TA sequence) at the first two positions of the sequence of oligoureas is tolerated and has limited 
influence on the overall helix geometry in the crystal.  
The chemical transformation of the thiourea moiety into a guanidininum was next evaluated on 
dimer 1b and tetramer 2b (Scheme 2). Direct conversion of the S-methylthiouronium intermediate 
14 derived from 1b in 7N ammonia in CH3OH gave the expected guanidinium-containing 
compound 15. However, RP-HPLC analysis of the crude product indicated that the guanidinylation 
product 15 was contaminated by several by-products and after flash silica gel chromatography 
dimer 15 was recovered in only 20% yield (Table 2, entry 1). 
Scheme 2. Two-step guanidinylation reaction of -residue-containing substrates 1-2b and 4.  
 
Much better results were obtained when the guanidinylation reaction was conducted in a non protic 
solvent like CH3CN. The reaction of S-methyluronium derivative of 2b with either 0.5M ammonia 
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in 1,4-dioxane or n-propylamine as nucleophile in CH3CN gave the expected guanidinium tetramers 
16 and 17 in 55% or 46% yield respectively after purification by silica gel chromatography (Table 
2, entries 3 and 4).  
 
Table 2. Outcome of the guanidinylation reaction of model γ-amino acid-containing oligo(thio)urea 
substrates 1b, 2b and 4. 
 
entry substrate nucleophile  equiv. of amine solvent
a time (h) cmpd  yield (%) 
1 1b 7N NH3 ~ 150 MeOH 48 
15 
20 
2 2b 
0.5M NH3/1,4-
dioxane 
45b CH3CN 90 16 55 
3 2b 
0.5M NH3/1,4-
dioxane 
40b THF 38 16 74 
4 2b nPrNH2 45
b CH3CN 90 17 46 
5 4 
0.5M NH3/1,4-
dioxane 
20 CH3CN  24 18 92 
6 4 nPrNH2  20
 
 CH3CN 60 19 60 
a
The reaction was carried out at 40-45°C; 
b
The amine was added in several portions depending on the progress of the 
reaction. 
 
These results motivated us to test these optimized conditions on a longer and potentially more 
folded oligomer. The selected hexamer 4 equipped with a -Leu at first position (sequence 
UUUUTA, Figure 2) and composed of the two triads with Val, Ala, Leu side-chains was 
synthesized in solution (see general procedure for details). Single crystals suitable for X-ray 
diffraction studies were obtained and as shown in Figure 3b (see supporting information for details), 
oligomer 4 adopts a well-defined helical structure in the crystal. An overlay with the known 
structure of the corresponding 6-mer homooligourea U6
8
 by fitting the six pairs of main chain 
asymmetric C atoms indicates a very close match (RMSD = 0.150 Å) between the two helices 
(Figure 3c). 
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Conversion of 6-mer 4 to the corresponding N,N'-di- or N,N’,N"-trisubstituted guanidinium-
containing oligomers 18 and 19 by treatment of its S-methylthiouronium salt with either 0.5 M 
ammonia solution in 1,4-dioxane or n-propylamine in CH3CN was straightforward (Scheme 2c and 
Table 2 entries 4 & 5). The conversion to 19 required 60 hours to reach completion whereas 
conversion to 18 was nearly complete after only 24h as monitored by RP-HPLC analysis. Both 
oligo(guanidinium/amide/urea) hybrids 18 and 19 were recovered in 92% and 60% yield 
respectively after silica gel chromatography purification.  
Guanidinylation reaction on solid support. We next applied this post-elongation guanidinylation 
method to the solid support with the aim to speed the access to more functionalized and biologically 
relevant sequences. We have recently reported an efficient solid phase methodology to prepare 
oligo(thio)ureas on TFA-labile resins.
36
 This optimized SPS protocol was applied here to synthesize 
a resin-bound 8-mer oligo(thiourea/amide/urea) hybrid on Rink-amide resin (20R) as a direct 
precursor for the guanidinylation steps (Scheme 3). This hybrid sequence derives from that of an 
antibacterial amphiphilic cationic oligourea sequence
4
and contains (1) a thiourea bond between 
residues 4 and 5 and (2) a -Lys residue at position 4 to prevent intramolecular guanidine 
formation. Activated azide succinimidyl carbamate monomers of type BB3 with the side-chains of 
Ala, Val, Lys and Phe were used for urea formation in combination with N-Fmoc-aminoalkyl 
isothiocyanate BB4 for thiourea insertion and commercially available N-Fmoc--Lys(Boc)-OH for 
amide bond formation. Because of the high reactivity of the indole side-chain towards methyl 
iodide, we employed a N-Boc protected version (BB5) of the Trp-derived azide building block 
during oligo(thio/amide/urea) hybrid SPS (Scheme 3 and see general procedure for details).
37
 
Successful elongation of the resin-bound oligomer 20R intermediate was confirmed by performing a 
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micro-TFA-cleavage of the resin. As depicted in scheme 3, the RP-HPLC profile of the crude 
material (20) showed a good purity, sufficient to continue with thiourea activation.  
Scheme 3. Post elongation and on-resin approach to introduce guanidinium linkages in urea-based 
foldamers. (a-f) Synthesis of the resin bound 8-mer oligo(thiourea/amide/urea) hybrid 20R; (g) S-
methylation of 20R and (h) guanidinylation reaction of 21R into 22R. The RP-HPLC chromatograms 
( = 200 nm) and ESI spectra correspond to the crude products isolated after each step (i.e. crude 
20, 21 and 22) following micro-TFA-cleavage of few resin beads. 
 
a
Reaction conditions: (a) BB3 or BB5, DIPEA, DMF, 70°C, 25 W (2  15 min); (b) PMe3, 1,4-dioxane/H2O, 70°C, 25 
W (2  30 min); (c) Fmoc--Lys(Boc)-OH, BOP, DIPEA, DMF, 70°C, 25 W (2  15 min); (d) DMF/piperidine; (e) 
BB4, DCM, 48h; (f) iPrNCO, DMF, 70°C, 25 W. 
The S-methylation of the resin-bound thiourea oligomer 20R was performed by treatment with CH3I 
in DMF under microwave irradiation at 40°C for 30 mins. The procedure was repeated 4 times to 
14 
 
ensure complete methylation. A micro-TFA-cleavage of the resin was performed to confirm the 
effective conversion of 20R into the resin-bound S-methylthiouronium iodide salt (21R). In Scheme 
3, the RP-HPLC profile essentially showed the presence of a single peak assigned to 21 by ESI-MS 
analysis. 
The resin-bound methylthiourea 21R was initially treated with 0.5 N ammonia in 1,4-dioxane under 
the conditions optimized in solution to access to 22. However, it appeared that the ammonia 
solution was not sufficiently concentrated to ensure conversion without an extended heating. 
Conversely, complete conversion to the resin-bound guanidinium 22R was obtained by treatment of 
21R with a saturated solution of ammonia gas in THF for 48 hours at 50°C. The purity of the crude 
product after TFA cleavage was estimated to be ≈ 66% by HPLC analysis. The expected 
guanidinium oligomer 22 was finally isolated in 17% overall yield (20 steps) after semi-preparative 
RP-HPLC. 
 
Effects on the conformation of thiourea  guanidinium replacements 
The consequences on the helical conformation of oligo(thio)urea hybrids of discrete thiourea  
guanidinium replacements were investigated by NMR and ECD. We concentrated on oligomers 12, 
18, 19, and 22 which differ by the relative position of the backbone guanidinium in the sequence.  
The guanidinium unit is located close to the C-terminus in compounds 18 and 19, whereas it 
occupies a more central position in 12 and 22. NMR spectra of all compounds and their 
oligo(thio)urea precursors were recorded in the range 1-3 mM in CD3CN (or CD3OH) and proton 
resonances were assigned by using combination of homonuclear COSY, TOCSY, ROESY and 
heteronuclear 
1
H-
13
C HSQC 2D experiments (see supporting information).  As shown in Figure 4 
for compounds 4, 18 and 19, thiourea and guanidinium NHs generally appear as broad signals and 
at higher frequencies compared to the urea NHs. Of note, the urea NH resonances of the two 
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guanidinium-containing 6-mers 18 and 19, are not significantly affected by the T  G replacement 
and display qualitative features typical of a well-folded conformation : dispersion over a large range 
of chemical shifts (5.0-6.8 ppm); large vicinal coupling constants with 
β
CH(R) protons (6-10 Hz) 
and a strong differentiation between vicinal coupling constants with diastereotopic -methylene 
(

CH2) protons of chiral diamine units.
 
 
 
Figure 4. Part of 
1
H NMR spectra (300 MHz) of oligomers 4, 18-19 in CD3CN (3mM) at 298 K, 
showing the NH region. The urea NHs signals are spread between 6.8 and 5.0 ppm. Thiourea NHs 
annotated with a star, guanidinium NHs annotated with a circle, amide NHMe annotated with a 
triangle. 
The chemical shift variation () of CH2 of urea units was measured as a mean to further evaluate 
the effect of the guanidinium replacement on folding. It is now well-established
2,33
 that when placed 
in a helical environment, the 

CH2 protons of U units exhibit a high degree of anisochronicity ( 
splitting) with  reaching values generally above 1 ppm. The Δδ values for urea residues in 18 and 
19 were found to be almost similar to those already reported for the cognate homo-urea 6-mer (U6)
8
 
and 4 suggesting that the helical structure running from residues 3-6 is not particularly affected by 
the introduction of the G and A units at positions 2 and 1.
38
 (Figure 5, bottom). Further insight into 
the relative folding propensity of 4 and 18 at the residue level was gained by comparing 
hydrogen/deuterium (H/D) exchange data of backbone urea and amide protons (see Figures S96-99 
and Tables S10 and S11 in supporting information). The first observation is that urea protons of 
central residues (NH and N’H of ValU3, LeuU4 and N’H of  AlaU5) exchange at slow rates in both 
16 
 
molecules (kex ≤ 10 × 10
−3
 min
−1
) supporting the view that folding from residue 3-6 is not affected 
by the T  G replacement. As expected, terminal urea protons (N’H of ValU6 and NH of AlaU5) and 
Boc-NH proton which are exposed to the solvent exchange at much higher rate in both molecules. 
In contrast urea NH of the second residue was found to exchange at faster rate in 18 compared to 4 
(72 × 10
−3
 min
−1 
vs 11 × 10
−3
 min
−1
). The same holds true for the terminal amide proton which 
exchanges at a rate of 275 × 10
−3
 min
−1 
in 4, but too fast for the rate to be determined in 18. This is 
further supported by the observation that the amide NHMe proton resonance which appears ≈8 ppm 
in 4 is upfield shifted upon guanidinium replacement. These results confirm that folding is largely 
maintained over the first four urea-based residues but that the folding propensity of residues 
neighbouring the G units is reduced or eliminated. NMR evaluation of compounds 12 and 22 
revealed a similar trend whereby the guanidinium moiety affects the helical character of the 
preceding residues in the sequence more significantly than those that follow. For example, a fall of 
anisochronicity at Leu
U1
 is observed in 12 compared to 3, whereas the anisochronicity at Leu
U4
, 
Ala
U5
 and Val
U6
 remains largely unchanged after the T  G replacement (Figure 5, top). 
anisochronicities at U units in 22 were quite revealing, showing that residues in i±2 relationship 
with the G unit (namely Trp
U3
 and Lys
U7
) are comparatively more affected than other residues in 
the sequence (see supporting information). This drop of anisochronicity can be explained by a 
significantly reduced folding propensity of the guanidinium moiety and concomitant loss of 
canonical intramolecular H-bonds. In contrast, the marginally weaker anisochronicity values at 
residues 2, 6 and 8 suggests that the overall geometry of these residues is maintained on this face of 
the helix.  
17 
 
 
Figure 5. Anisochronicity at urea residues in oligo(thio/amide)urea 3 and 4 as well as related 
guanidinium hybrids 12, 18, and 19.  Ratios to the values measured for the cognate oligourea U6
8
are 
reported. 
 
Although ECD has been used extensively to characterize helix formation among homoligoureas,
33
 
its potential utility here, is complicated by the presence of multiple chromophores (ureas, thioureas 
and amides).
6,8
 Nevertheless, ECD analysis can provide qualitative information about the ability of 
modified oligomers to retain the typical signature (maximum of positive molar ellipticity [θ] ≈ 203 
nm and a trough of weaker intensity at ≈ 188 nm) attributable to 2.5-helix formation. The ECD 
spectra of compounds 4, 18 and 19 were measured at a concentration of 0.2 mM in 2,2,2-
trifluoroethanol (TFE) and compared to that of the corresponding homooligourea U6
8
 (Figure 6). 
The CD signatures  of 18 and 19 which contain a thiourea  guanidinium replacement close to the 
C-terminus are reminiscent of that of the parent oligourea U6 and have the hallmarks of a folded 
18 
 
structure in agreement with NMR analysis. A similar trend is observed when analysing the ECD 
spectrum of 22 (see Figure S95 in supporting information) 
 
Figure 6. ECD spectra of oligomers 4, 18 and 19 compared to that of the cognate homo-oligourea 
U6
8
 (all spectra were recorded in TFE at 0.2 mM). 
CONCLUSIONS 
The present work further expands the range of urea surrogates that can be introduced in the 
backbone of aliphatic oligourea foldamers to modulate their properties. While some of our earlier 
work focused on amide (A), carbamate (C) and thiourea (T) isosteric units, we have now exploited 
the reactivity of thioureas to introduce guanidinium linkages (G) at a late stage in the synthesis and 
possibly convert oligo(thio)ureas into the corresponding guanidinium/urea oligomers in a two-step 
procedure. One limitation of this approach was the competition with an intramolecular backbone 
cyclization that resulted in the formation of oligomers with heterocyclic guanidinium. Although this 
side reaction could be minimized by using moderately polar and non protic solvents, we found that 
the insertion of an isostructural -amino acid residue before the thiourea linkage was a simple 
alternative to cleanly install the guanidinium group in the sequence. By capitalizing on an efficient 
solid-phase synthesis of oligo(thio)ureas, we have adapted the guanidinylation procedure to solid 
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support enabling fast elaboration of urea-based oligomers containing backbone guanidiniums. 
Conformational studies in solution by NMR and ECD associated with XRD analyses confirm that 
the combination of a thiourea unit and a -amino acid residue and (T-A pair) in oligomeric 
precursors is compatible with helical folding with little deviation from the canonical 2.5-helical 
structure of oligoureas. Although spectroscopic characteristics of partially folded structures remain 
in oligoureas containing a guanidinium moiety, folding is significantly disrupted by the 
guanidinium replacement. A future goal of our research is to characterize the structures of 
oligo(urea/guanidinium) foldamers at atomic resolution using X-ray diffraction. It could also be of 
interest to evaluate how the nature of the counterion of the guanidinium linkage may affect the 
propensity for the oligomer to fold or unfold.
39-44
  
Another development of this work facilitated by the compatibility with SPS techniques will be to 
evaluate the impact of such backbone modifications on the biological activities of foldamers in 
terms of recognition of biological surfaces and also cell penetration. Encouraging results have 
recently been obtained with derivatives of membrane-active antibacterial oligoureas containing 
various surrogate units including guanidinium.
37
 
 
EXPERIMENTAL SECTION 
General procedures. All solvents and reagents were obtained from commercial sources. Rink 
amide MBHA resin (loading 0.52 mmol/g) was purchased from Merck-Millipore. Fmoc--
Lys(Boc)-OH and benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexa-fluorophosphate 
(BOP) reagent were purchased from PolyPeptide Laboratories France. Solid phase peptide synthesis 
grade organic solvents (DMF, DCM) were used for solid phase synthesis and were purchased from 
Carlo Erba. RP-HPLC-quality acetonitrile (CH3CN) and MilliQ water were used for RP-HPLC 
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analyses and purification. Anhydrous solvents were dispensed from a solvent purification system 
(DCM, THF). Thin layer chromatography (TLC) was performed on silica gel 60 F254 (Merck) with 
detection by UV light and charring with 1% ninhydrin in ethanol followed by heating. Flash column 
chromatography was carried out on silica gel (40-63 μm, Merck). Chemical shifts are reported in 
parts per million (ppm, δ) relative to the 1H or 13C residual signal of the deuterated solvent used. 1H 
NMR splitting patterns with observed first-order coupling are designated as singlet (s), broad singlet 
(bs), doublet (d), triplet (t), or quartet (q). Coupling constants (J) are reported in hertz.  
Analytical RP-HPLC analyses were performed on a Dionex U3000SD using a Macherey-Nagel 
Nucleodur column (4.6 × 100 mm, 3 μm) at a flow rate of 1 mL.min-1. The mobile phase was 
composed of 0.1% (v/v) TFA-H2O (Solvent A) and 0.1% TFA-CH3CN (Solvent B). The detection 
was performed at 200 nm and the column temperature in the oven was 25°C. Semi-preparative 
purifications of oligoureas were performed on a Dionex U3000SD system using a Macherey-Nagel 
Nucleodur column (100-6 C18ec, 10  250 mm, 5 μm) at a flow rate of 4 mL.min-1. The mobile 
phase was similar as for the analytic system, unless otherwise notified.  
Activated (S)-succinimidyl-{2-{[(tert-butoxy)carbonyl]amino}-2-X-ethyl}carbamate monomers 
BB1 and BB3 for the introduction of urea bonds and activated (S)-tert-butyl (1-(1H-
benzo[d][1,2,3]triazole-1-carbothioamido)propan-2-yl)carbamate BB2 used for the introduction of 
thiourea unit were prepared from corresponding N-Boc protected ethylene diamine derivatives 
using recently reported procedures.
5,8,33
 Compound 3 was synthesized as described previously.
8
 
Solid-phase oligourea synthesis was performed manually under microwave irradiation (vide infra) 
on the Discover® System from CEM (CEM MWaves S.A.S., Orsay, France) using open reaction 
vessels and internal fiber optic temperature control. 
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Urea Formation in solution: General Procedure I. Boc-protected oligourea (1.0 equiv.) was 
dissolved in TFA (3 mL/g) cooled down in an ice/water bath and the reaction mixture was stirred at 
room temperature for 50 min under N2 atmosphere. The reaction mixture was concentrated under 
reduced pressure, and the resulting residue was co-evaporated three times with cyclohexane. The 
crude product was then dissolved in CH3CN (5 mL/1.5 mmol). DIPEA (3.0 equiv.) was added, and 
the mixture was cooled down to 0 °C prior to the dropwise addition of the following activated 
carbamate BB1 (1.1 equiv.), dissolved in CH3CN (5 mL). The pH of reaction must be basic, so if 
required additional portion of DIPEA was added. After completion of the reaction, the reaction 
mixture was evaporated under reduced pressure, dissolved in EtOAc, and washed with 1 M KHSO4 
solution, saturated solution of NaHCO3 and brine. The organic layer was then dried over Na2SO4 
and evaporated under reduced pressure. Flash column chromatography (CH2Cl2−MeOH (v/v), 98:2 
to 95:5) over silica gel or trituration with Et2O gave the expected compound.  
Thiourea Formation: General Procedure II. Boc-protected oligourea (1 equiv.) was treated with 
TFA (3 mL/g) cooled down in an ice/water bath and the reaction mixture was stirred at room 
temperature for 50 min under N2 atmosphere. The reaction mixture was then concentrated under 
reduced pressure, and the resulting residue was co-evaporated three times with cyclohexane. The 
crude product was dissolved in CH3CN (5 mL/1.5 mmol). DIPEA (3.0 equiv.) was then added, and 
the mixture was cooled down to 0 °C prior to the dropwise addition of the 
thiocarbamoylbenzotriazole derivative BB2 (1equiv.) dissolved in CH3CN-CH2Cl2 (85:15, 7mL). 
The pH of reaction should be around 8, so if required additional amount of DIPEA was added. The 
reaction mixture was left to come back to RT and stirred overnight. CH3CN was then evaporated 
under reduced pressure and the crude mixture was dissolved in EtOAc, washed twice with 1 M 
KHSO4 solution, saturated solution of NaHCO3, water and brine, dried over MgSO4 and evaporated 
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under reduced pressure. Flash column chromatography (CH2Cl2−MeOH (v/v), 98:02 to 95:05) over 
silica gel gave the desired compound. 
Heterodimer Boc-Ala
T
-Leu
U
-NHMe (1a). 1a was prepared from Boc-Leu
U
-NHMe (0.410 g, 1.5 
mmol) and BB2 (0.48 g, 1.5 mmol) as described in the general procedure II (0.52 g, 89%). 
1
H 
NMR (DMSO-d6, 300 MHz) δ 7.40 (bs, 2H), 6.80 (bs, 1H), 5.84 (bd, 2H), 4.33 (bs, 1H), 3.62 (bs, 
1H), 3.50-3.22 (m, 3H), 3.17-2.98 (m, 2H), 2.56 (d, J = 4.6 Hz, 2H), 1.61 (m, J = 6.0 Hz, 1H), 1.41 
(s+m, 10H), 1.29-1.19 (m, 1.5H), 1.02 (d, J = 6.6 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 
6.6 Hz, 3H); 
13
C NMR (CD3OD, 125 MHz) δ 182.9, 162.0, 158.3, 80.2, 54.1, 50.1, 47.6, 46.1, 42.6, 
28.8, 27.1, 26.1, 23.7, 22.6, 18.7. HRMS (ESI-TOF) m/z: [M + Na]
+
 Calcd for C17H35N5O3NaS 
412.2358; Found 412.2350. C18 RP-HPLC (10−100% B in 10 min): tR = 7.03 min. 
Boc-Val
U
-Ala
T
-Leu
U
-NHMe (24): 24 was prepared from 1a following general procedure I White 
solid  (0.49g, 71%) , 
1
H NMR (CD3CN, 300 MHz) δ 6.96 (bs, 1H), 6.79 (bs, 1H), 5.93 (bs, 1H), 
5.59 (bs, 1H), 5.39 (d, J = 10.5, 1H), 5.27 (t, J = 6.4, 1H), 4.98 (bs, 1H), 4.64 (bs, 1H), 4.15 (bs, 
2H), 3.72 (bs, 1H), 3.55-3.45(m, 2H), 2.65 (d+bs, J = 4.7, 5H), 1.73-1.57 (m, 2H), 1.34-1.27 (m, 
2H), 1.07 (d, J = 6.8, 3H), 0.97-0.87 (m, 12H); tR = 7.60 min. (10−100% B in 10 min); ESI-MS (+): 
517.3 [M+H]
+
, 1035.7 [2M+H]
+
. 
Boc-Leu
U
-Val
U
-Ala
T
-Leu
U
-NHMe (2a). 2a was prepared from 24 as described in the general 
procedure I and was isolated as a white solid (0.46g, 74%). 
1
H NMR (DMSO-d6, 300 MHz) δ 7.36 
(bs, 2H), 6.67 (d, J = 6.8, 1H), 6.17-5.74 (m, 6H), 4.42 (bs, 1H), 3.89 (bs, 2H), 3.56-3.41 (m, 2H), 
3.35-3.22 (m, 3H), 3.12-3.04 (m, 2H), 2.84 (bs, 2H), 2.56 (d, J = 4.7 Hz, 3H), 1.69-1.54 (m, 3H), 
1.41 (s, 9H), 1.30-1.10 (m, 4H), 1.00 (d, J = 6.5 Hz, 3H), 0.9-0.81 (m, 18H); 
13
C NMR (CD3OD, 
125 MHz) δ 185.7, 162.2, 161.3, 161.2, 159.2, 80.2, 56.5, 53.6, 51.7, 50.1, 49.3, 46.6, 46.1, 45.8, 
44.8, 43.4, 42.4, 31.9, 28.9, 26.9, 26.3, 26.1, 23.7, 23.5, 23.0, 22.7, 20.1, 19.0, 18.7. HRMS (ESI-
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TOF) m/z: [M + Na]
+
 Calcd for C30H61N9O5NaS 682.4414; Found 682.4431. C18 RP-HPLC 
(10−100% B in 10 min): tR = 9.29 min. 
Boc-γ-Leu-NHCH3 (25): Boc-γ-Leu-OH (1.4 g, 5.4 mmol) was suspended in CH3CN (50 mL) and 
cooled in ice/water bath. After addition of DIPEA (3.76mL, 21.6 mmol) all the suspension was 
dissolved. HBTU (2.46 g, 6.48 mmol) was added and the reaction mixture was stirred for 10 min. at 
0°C. Methylamine hydrochloride (0.73 g, 10.8 mmol) was added in one portion. The reaction 
mixture became green and after 10 min. yellow. The reaction was left to reach RT and magnetic 
stirring was maintained overnight. CH3CN was evaporated and the residue was dissolved in EtOAc 
(80 mL), washed with 1M KHSO4 (5  35 mL), NaHCO3 (3  35 mL, emulsion), brine (1  35 
mL), dried over Na2SO4. The crude product was directly engaged to the next step without 
purification. Yellowish solid; (1.44g, 98% (crude, purity >95%)), 
1
H NMR (CDCl3, 300 MHz) δ 
6.46 (bs, 1H), 4.30 (d, J = 9.7, 1H), 3.71-3.59 (m, 1H), 2.85 (d, J = 4.8, 3H), 2.25 (t, J = 6.9, 2H), 
1.92-1.81 (m, 1H), 1.75-1.54 (m, 1H), 1.48 (s, 9H), 1.38 – 1.21 (m, 2H), 0.93 (d, J = 6.7, 3H), 0.92 
(d, J = 6.5, 3H); tR = 6.93 min. (10−100% B in 10 min); ESI-MS (+): 273.2 [M+H]
+
, 545.4 
[2M+H]
+
. 
Boc-Ala
T
-Leu-NHMe (1b). 1b was prepared according to procedure II starting from 25 (1.44 g, 
5.3 mmol) and activated monomer BB2 (1.73 g, 5.4 mmol) and was obtained as a white foam (1.5 
g, 69%). 
1
H NMR (CD3CN, 300 MHz) δ 6.55+6.27 (s+bs, 2H), 5.58 (bs, 1H), 4.48 (bs, 1H), 3.75 
(bs, 2H), 3.46 (bs, 2H), 2.70 (d, J = 4.6 Hz, 3H), 2.29-2.16 (m, 2H), 1.77-1.60 (m, 2H), 1.44 (s+m, 
10H), 1.35-1.26 (m, 2H), 1.13 (d, J = 6.7 Hz, 3H), 0.95-0.92 (m, 6H); 
13
C NMR (CD3OD, 125 
MHz) δ 176.5, 158.4, 80.2, 53.4, 50.0, 47.8, 45.7, 33.7, 33.1, 28.8, 26.4, 26.1, 23.6, 23.0, 18.8. 
HRMS (ESI-TOF) m/z: [M + Na]
+
 Calcd for C18H36N4O3NaS 411.2406; Found 411.2396. C18 RP-
HPLC (10−100% B in 10 min): tR = 7.25 min. 
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Boc-Val
U
-Ala
T
-γLeu-NHMe (26): 26 was prepared from 1b according to the general procedure I. 
White solid, (0.83g, 79%, flash chromatography CH2Cl2/CH3OH, 98:2 to 95:5), 
1
H NMR (CD3CN, 
300 MHz) δ 7.63 (bs, 1H), 6.93 (bs, 1H), 6.77 (bs, 1H), 5.37 (d, J = 9.8, 1H), 5.20 (t, J = 6.0, 1H), 
4.99 (bs, 1H), 4.53 (bs, 1H), 4.28 (bs, 1H), 3.98 (bs, 1H), 3.58 (bs, 1H), 3.43 (bs, 1H), 2.36-2.23 (m, 
2H), 2.67 (d+bs, J = 4.7, 4H), 1.71-1.60 (m, 2H), 1.47 (s, 9H), 1.38-1.24 (m, 3H), 1.08 (d, J = 6.8, 
3H), 0.96-0.87 (m, 12H); tR = 7.72 min. (10−100% B in 10 min); ESI-MS (+): 517.4 [M+H]
+
, 
1033.7 [2M+H]
+
. 
Boc-Leu
U
-Val
U
-Ala
T
-Leu-NHMe (2b). 2b was prepared from 26 as described in the general 
procedure I and was isolated as a white solid (1.6g, 88%). 
1
H NMR (CD3CN + 3% CDCl3, 300 
MHz) δ 7.81 (s, 1H), 7.45 (d, J = 6.0 Hz, 1H), 7.16 (d, J = 8.9 Hz, 1H), 5.51-5.44 (m, 3H), 5.36 (d, 
J = 10.0 Hz, 1H), 4.97 (d, J = 10.2 Hz, 1H), 4.58 (bm, 1H), 4.39 (bm, 1H), 4.13-4.03 (bm, 1H), 
3.87 – 3.74 (m, 1H), 3.68-3.53 (m, 2H), 3.47 (ddd, J = 14.0 Hz, 7.7, 3.6, 1H), 2.68 (d, J = 4.7 Hz, 
3H), 2.60-2.43 (m, 2H), 2.39-2.24 (m, 3H), 2.1-2.02 (m, 1H), 1.73-1.54 (m, 3H), 1.49 (s, 9H), 1.33-
1.18 (m, 6H), 1.03 (d, J = 6.8, 3H), 0.97-0.85 (m, 18H); 
13
C NMR (CD3OD, 125 MHz) δ 184.8, 
176.6, 161.3, 161.1, 159.1, 80.2, 56.5, 52.5, 51.3, 50.0, 46.7, 46.4, 46.3, 44.8, 42.4, 33.6, 31.8, 31.8, 
28.9, 26.5, 26.3, 26.2, 23.6, 23.6, 23.2, 22.7, 20.3, 19.3, 18.4. mp 206−207 °C. HRMS (ESI-TOF) 
m/z: [M + Na]
+
 Calcd for C31H62N8O5NaS 681.4462; Found 681.4470. C18 RP-HPLC (10−100% B 
in 10 min): tR = 9.23 min. 
Boc-Ala
U
-Leu
U
-Val
U
-Ala
T
-γLeu-NHMe (27): 27 was prepared from 2b according to the general 
procedure I. White solid  (0.71g, 79%), 
1
H NMR (CD3CN +3% CDCl3, 300 MHz) δ 7.93 (bs, 1H), 
7.61 (d, J = 6.8, 1H), 7.21 (d, J = 8.9, 1H), 6.37 (d, J = 8.8, 1H), 5.89-5.81 (m, 2H), 5.64 (d, J = 
10.3, 1H), 5.51-5.48 (m, 2H), 4.96 (d, J = 10.0, 1H), 4.58 (bm, 1H), 4.44 – 4.34 (m, 1H), 4.15-4.05 
(m, 1H), 3.98-3.85 (m, 1H), 3.80-3.45 (m, 6H), 2.68 (d, J = 4.6, 3H), 2.58 – 2.49 (m, 2H), 2.43-2.24 
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(m, 4H), 2.11-2.02 (m, 1H), 1.73-1.54 (m, 3H), 1.49 (s, 9H), 1.38-1.20 (m, 6H), 1.09 (d, J = 6.9, 
3H), 1.03 (d, J = 6.9, 3H), 0.98-0.91 (m, 18H); tR = 9.98 min. (10−100% B in 10 min then 100% B 
for 3 min); ESI-MS (+): 759.5 [M+H]
+
, 1518.1 [2M+H]
+
. 
Boc-Val
U
-Ala
U
-Leu
U
-Val
U
-Ala
T
-Leu-NHMe (4): 4 was prepared as described in the general 
procedure I and was isolated as a white solid (1.1g, 72% yield). 
1
H NMR (CD3CN, 300 MHz, see 
also Table S1) δ 7.94 (s, 1H), 7.68 (d, J = 7.5 Hz, 1H), 7.24 (d, J = 9.3 Hz, 1H), 6.55 (dd, J = 9.7 
Hz, 2.6, 1H), 6.39 (dd, J = 9.9 Hz, 2.6 Hz, 1H), 6.18 (d, J = 10.7 Hz, 1H), 5.81 (d, J = 10.2 Hz, 
1H), 5.78 (d, J = 9.7 Hz, 1H), 5.73 (dd, J = 9.9 Hz, 3.3 Hz, 1H), 5.46-5.41 (m, 2H), 5.04 (d, J = 
10.0 Hz, 1H), 4.65-4.53 (m, 1H), 4.49-4.32 (m, 1H), 4.17-4.02 (m, 1H), 3.98-3.79 (m, 2H), 3.72-
3.46 (m, 6H), 2.68 (d, J = 4.7 Hz, 3H), 2.61-2.49 (m, 2H), 2.43-2.24 (m, 5H), 2.1-2.02 (m, 1H), 
1.77-1.55 (m, 4H), 1.50 (s, 9H), 1.38-1.28 (m, 3H), 1.24-1.17 (m, 2H), 1.08-0.81 (m, 30H); 
13
C 
NMR (CD3OD, 75 MHz) δ 175.1, 160.5, 160.5, 160.3, 160.2, 160.2, 159.5, 158.3, 79.0, 56.4, 54.6, 
51.2, 50.1, 46.1, 46.0, 45.5, 44.9, 43.3, 42.60, 41.5, 32.2, 30.7, 30.5, 27.5, 25.1, 25.0, 24.8, 22.3, 
22.2, 21.9, 21.4, 18.9, 18.8, 17.9, 17.7, 16.9, 16.7. mp 208−209 °C. HRMS (ESI-TOF) m/z: [M + 
Na]
+
 Calcd for C41H82N12O7NaS 909.6048; Found 909.6066. C18 RP-HPLC (10−100% B in 10 min 
then 100% of B for 3 min): tR = 11.56 min. 
S-methylation reaction: General procedure III. To a solution of oligo(thio)urea (0.35 mmol in 20 
mL) in a mixture of CH3CN/THF (1:1, v/v) was added CH3I (10 equiv.). The flask was tightly 
closed with a septum and the mixture was heated to 40-45°C. The monitoring of reaction was 
performed by RP-HPLC analysis. The reaction was completed after 2-5 hours. The solvent was 
evaporated and the crude material was directly engaged to the following step without any further 
purification.  
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Guanidinylation reaction with 7N NH3 in CH3OH: General procedure IV. The thiouronium 
iodide oligomer (0.14 mmol in 2 mL) was dissolved in a 7N ammonia solution in methanol, the 
flask was tightly closed with a septum and the reaction mixture was stirred at 40-45°C. The 
monitoring of the reaction was performed by RP-HPLC analysis. After 24-48 hours the reaction 
media was concentrated by evaporation under reduced pressure and the crude mixture was directly 
separated by silica gel column chromatography or semi-prep HPLC. In all cases, cyclic and/or 
linear substituted guanidiniums were formed. 
Compounds 5 and 7. 5 and 7 were prepared from thiouronium iodide salt 6 according to the 
general procedure III and were isolated in a ratio of 33/67 after silica gel flash column 
chromatography (CH2Cl2−CH3OH (v/v), from 98:2 to 95:5).  
Compound 5 was recovered as a yellowish film in 11% yield (4 mg). 
1
H NMR (CDCl3, 300 MHz) 
δ 7.64 (bs, 1H), 7.42 (bs 2H), 6.13 (bs, 1H), 5.30 (bs, 1H), 4.82 (bs, 1H), 3.67 (bs, 1H), 3.56-3.41 
(bm, 2H), 3.32-3.24 (m, 1H), 3.03 (dd, J = 14.0, 6.4 Hz, 1H), 2.78 (d, J = 4.8 Hz, 3H), 1.46 (s, 9H), 
1.31 (d, J = 6.7 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H), 0.89 (d, J = 6.5 Hz, 2H). 
13
C (CDCl3, 125MHz, 
cryoprobe) δ 160.5, 156.8, 156.7, 81.1, 51.3, 47.3, 47.0, 46.2, 29.7, 28.4, 28.3, 27.0, 24.9, 23.2, 
21.5, 18.4. HRMS (ESI-TOF) m/z: [M]
+
 Calcd for C17H37N6O3 373.2927; Found 373.2930. C18 RP-
HPLC (10−100% B in 10 min): tR = 5.71 min. 
Compound 7 was recovered as a yellowish film in 26% yield (12 mg); 
1
H NMR (CDCl3, 300 MHz) 
δ 9.64 (s, 1H), 9.48 (b sign, 0.5H), 7.47 (bs, 1H), 4.94 (d, J = 4.6 Hz, 1H), 4.68 (t, J = 8.8 Hz, 1H), 
4.30-4.20 (m, 1H), 4.14-4.09 (m, 1H), 3.69-3.57 (m, 2H), 3.39 (m, 1H), 2.88 (d, J = 4.5 Hz, 3H), 
2.02-1.89 (m, 1H), 1.85-1.79 (m, 1H), 1.58-1.54 (m, 1H), 1.47 (s, 9H), 1.34 (d, J = 6.6 Hz, 3H), 
1.00 (t, J = 6.6 Hz, 6H); 
13
C NMR (HSQC, CDCl3, 75MHz) 52.8, 52.2, 49.0, 46.5, 43.8, 29.5, 28.0, 
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24.2, 22.5, 22.5, 18.1. HRMS (ESI-TOF) m/z: [M]
+
 Calcd for C17H34N5O3 356.2662; Found 
356.2668.
 
C18 RP-HPLC (10−100% B in 10 min): tR = 6.04 min. 
Compounds 8 and 9. 8 and 9 were prepared from 2a on a small scale (0.023 mmol) according to 
the general procedure III and IV and were formed in a ratio of 26/74. They were isolated after 
purification by semi-preparative RP-HPLC (25-65% B in 20 min).  
Compound 8. 
1
H NMR (CD3CN, 300 MHz) δ 7.50 (bs, 1H), 7.36 (bs, 1H), 7.13 (bs, 1H), 6.17 (bs, 
1H), 6.06 (bs,1H), 5.70-5.62 (m, 3H), 5.49 (bs,1H), 5.42 (d, J = 9.9 Hz, 1H), 3.98 (bs, 1H), 3.79-
3.68 (m, 1H), 3.64-3.43 (m, 3H), 3.40-3.21 (m, 3H), 3.05 (bs, 1H), 2.84 (bs, 1H), 2.69 (d, J = 4.5 
Hz, 3H), 2.66-2.56 (m, 1H), 2.50-2.43 (m, 1H),  1.76-1.57 (m, 3H), 1.45 (s, 9H), 1.43-1.36 (m, 2H), 
1.27-1.15 (m, 2H), 1.09 (d, J = 6.7 Hz, 3H), 0.95-0.89 (m, 18H); 
13
C NMR (CD3OD, 125 MHz, 
cryoprobe) δ 162.0, 161.5, 161.1, 159.2, 158.1, 80.3, 56.8, 56.4, 56.4, 52.4, 50.0, 46.6, 46.1, 45.6, 
44.7, 42.7, 42.4, 31.9, 28.9, 26.2, 26.1, 23.5, 23.5, 22.6, 22.2, 20.2, 18.7, 18.6. HRMS (ESI-TOF) 
m/z: [M]
+
 Calcd for C30H63N10O5 643.4983; Found 643.4974. C18 RP-HPLC (10−100% B in 10 
min): tR = 7.45 min. 
Compound 9: 
1
H NMR (DMSO-d6, 300 MHz) δ 9.63 (s, 1H), 9.40 (t, J = 6.2 Hz, 1H), 7.63 (d, J = 
4.2 Hz, 1H), 6.57 (d, J = 8.7 Hz, 1H), 6.29-6.20 (m, 1H), 5.97-5.92 (m, 2H), 5.76 (bs, 2H), 4.10 (bd, 
J = 4.3 Hz, 2H), 3.78-3.43 (m, 5H), 3.25-2.80 (m, 7H), 2.69 (d, J = 4.1 Hz, 3H), 1.75-1.44 (m, 6H), 
1.38 (s, 9H), 1.29-1.21 (m, 4H), 1.07 (d, J = 6.7 Hz, 3H), 0.94-0.80 (m, 18H); 
13
C NMR (HSQC, 
CD3CN, 125 MHz) δ 54.1, 51.4, 48.5,  48.4, 45.1, 44.1, 43.1, 40.6, 29.6, 27.1, 24.8, 24.0, 23.5, 
21.7, 21.1, 20.6, 18.3, 17.1. HRMS (ESI-TOF) m/z: [M]
+
 Calcd for C30H60N9O5 626.4717; Found 
626.4697. C18 RP-HPLC (10−100% B in 10 min): tR = 7.26 min. 
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Compound 9 (reaction in the presence of DIPEA). S-methylated tetramer 10 (0.017 mmol) was 
dissolved in MeOH (0.5 mL) and DIPEA was added (5 equiv., 15µL). The flask was closed with 
septum and the mixture was heated to 40-45°C. Cyclic product 9 was formed after 24 hours of 
stirring. The product was purified by semi-preparative RP-HPLC (30-100% B in 20 min) and ESI-
MS analysis confirmed the formation of 9. 
Compound 12. Compound 12 was obtained from 3 (scale 0,035 mmol) according to the general 
procedures III and VI (THF as co-solvent) with a conversion of 56% for the guanidylation step 
using 60 equiv. of 0.5 M NH3 in 1,4-dioxane (150h). The ratio of linear product 12 versus cyclic 
product 13 was 75/25. Compound 12 was isolated after semi-preparative RP-HPLC purification 
(40-60% B in 20 min). White solid. 
1
H NMR (CD3OH, 700 MHz, see also Table S4) δ 7.30 (m, 
NH), 6.65 (d, NH), 6.58 (m, NH), 6.40-6.37 (d, NH), 6.05-6.00 (m, NH), 5.95-5.87 (m, NH), 3.94 
(m,1H), 3.87 (m,1H), 3.77-3.72 (m,2H), 3.69 (m,1H), 3.65-3.58 (m,2H), 3.55-3.48 (m, 2H), 3.46 
(m,1H), 3.27 (m,1H), 3.16 (m,1H), 3.08-3.03 (m,2H), 2.87 (m,1H), 2.69 (d,3H), 2.56 (m,1H), 2.38-
2.30 (m,2H), 1.75 (m,1H), 1.72-1.65 (m,2H),1.63 (m,1H),1.47 (s,9H),1.30 (m,2H),1.23-1.13 
(m,5H), 1.03 (d,3H), 0.98-0.94 (dd,6H), 0.93-0.88 (m,18H). 
13
C NMR (CD3OH, 700 MHz) δ 
56.5,53.5, 48.9, 48.2,47.8, 47.2, 45.9, 45.1, 44.9, 44.4, 42.7, 41.6,44.4, 35.1, 30.6, 30.4,29.3, 27.4 
(3C), 26.7, 25.9, 24.8, 22.3, 20.9 (2C), 18.7 (2C), 17.6, 16.9, 16.1,13.03. HRMS (ESI-TOF) m/z: 
[M]
+
 Calcd for C40H83N14O7 871.6564; Found 871.6545. RP-HPLC (10−100% B in 10 min then 
100% B for 2 min): tR = 8.22 min. 
Compound 15. 15 was prepared from 1b according to general procedure III and IV in CH3OH and 
was recovered in 20% yield (10mg). 
1
H NMR (CD3CN, 300 MHz) δ 7.53 (bs, 1H), 7.15 (bs, 2H), 
6.83 (s, 1H), 5.72 (s, 1H), 3.61 (bs, 2H), 3.34-3.26 (bm, 1H), 3.14-3.04 (bm, 1H), 2.72 (d, J = 4.8 
Hz, 3H), 2.35 – 2.27 (m, 2H), 1.88-1.60 (m, 4H), 1.46 (s, 9H), 1.42-1.30 (m, 1H), 1.21 (d, J = 6.7 
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Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H); 
13
C NMR (HSQC, CD3CN, 75MHz) δ 
50.2, 46.6, 46.2, 42.3, 31.2, 30.1, 27.1, 25.3, 24.6, 22.3, 20.8, 16.5. HRMS (ESI-TOF) m/z: [M]
+
 
Calcd for C18H38N5O3 372.2969; Found 372.2984. C18 RP-HPLC (10−100% B in 10 min): tR = 5.88 
min. 
Guanidinylation reaction with n-propylamine: General procedure V. S-methylated oligomer 
intermediate was dissolved in CH3CN or CH3OH (0.034 mmol/mL) and n-propylamine (10 equiv.) 
was added. The flask was closed tightly with septum and the reaction mixture was heated to 40-
45°C. The monitoring of the reaction was performed by RP-HPLC analysis. Additional amounts of 
n-propylamine were added regularly. Reaction was stopped when no further progress was observed 
by RP-HPLC analysis.  
Compounds 9 and 11: 9 and 11 were prepared on small scale (0.034 mmol) in CH3CN from 2a 
according to the general procedures III and V in the presence of n-propylamine (45 equiv.) for 120 
hours. The ratio of linear tetramer 11 versus cyclic product 9 was 73/27 and both compounds were 
isolated after semi-preparative RP-HPLC purification (30-100% B in 20 min). Yields after 
purification for compound 9 was 16% and for compound 11 was 26%.  
When the reaction was performed in CH3OH in presence of n-propylamine (20 equiv.) after 24 
hours compound 11 and 9 were obtained in a ratio of 15/85 and were isolated after semi-RP-HPLC 
purification (30-100% B in 20 min). 
Compound 11. 
1
H NMR (CD3CN, 300 MHz, see also Table S3) δ 6.02 (bs, 1H), 5.39 (d, J = 6.9, 
1H), 5.08 (bs, 1H), 3.83 (bm, 1H), 3.71 (bm, 1H), 3.59 (bm, 3H), 3.33 (dd, J = 14.0 Hz, 3.4 Hz, 
2H), 3.21-3.15 (m, 3H), 3.08-3.00 (m, 1H), 2.94 (dd, J = 14.2 Hz, 6.7 Hz, 1H), 2.68 (s, 3H), 2.66-
2.52 (m, 2H), 1.76-1.62 (m, 5H), 1.46 (s, 9H), 1.42-1.21 (m, 3H), 1.18 (d, J = 6.8 Hz, 3H), 1.02-
0.88 (m, 21H); 
13
C NMR (HSQC, CD3CN, 75MHz) δ 54.7, 51.2, 49.0, 48.6, 45.6, 45.1, 44.8, 43.0, 
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42.7, 40.9, 40.4, 30.0, 27.7, 25.5, 24.4, 22.1, 21.4, 20.6, 18.7, 17.4, 17.2, 10.4. HRMS (ESI-TOF) 
m/z: [M]
+
 Calcd for C33H69N10O5 685.5452; Found 685.5467. C18 RP-HPLC (10−100% B in 10 
min): tR = 7.81 min. 
Compound 17. 17 was obtained from 2b after 90 hours according to the general procedures III and 
V (conversion 82% for the guanidylation step, 45 equiv. n-propylamine, CH3CN) as a yellowish 
foam in 46% yield after silica gel flash column chromatography (CH2Cl2−CH3OH (v/v), from 98:2 
to 92:8). 
1
H NMR (CD3CN, 300 MHz, see also Table S5) δ 8.02 (bs, 1H), 6.96 (bs, 1H), 6.00 (d, J = 
6.0 Hz, 1H), 5.74 (dd, J = 8.0 Hz, 3.4, 1H), 5.49 (pseudo-t, J = 6.0 Hz, 1H), 5.42 (d, J = 9.7 Hz, 
1H), 5.17 (d, J = 9.6 Hz, 1H), 3.88 – 3.72 (m, 1H), 3.70-3.51 (m, 4H), 3.35-3.27 (m, 2H), 3.21 (q, J 
= 9.6 Hz, 2H), 3.10 – 2.98 (m, 1H), 2.71 (d, J = 4.7 Hz, 3H), 2.68-2.58 (m, 2H), 2.31 (t, J = 6.2 Hz, 
2H), 1.76-1.62 (m, 6H), 1.46 (s, 9H), 1.38-1.22 (m, 3H), 1.19 (d, J = 6.7 Hz, 3H), 1.03-0.87 (m, 
21H); 
13
C NMR (CD3CN, 75MHz) δ 54.7, 50.0, 48.6, 46.1, 45.0, 42.9, 42.4, 41.0, 30.9, 30.1, 27.9, 
25.0, 24.7, 21.8, 21.3, 20.6, 18.5 17.4, 10.4. HRMS (ESI-TOF) m/z: [M]
+
 Calcd for C34H70N9O5 
684.5500; Found 684.5491. C18 RP-HPLC (10−100% B in 10 min): tR = 6.04 min. 
Compound 19. 19 was obtained from 4 after 60 hours according to the general procedures III and 
V (conversion 96% for the guanidylation step, 20 equiv. of n-propylamine) as a yellowish foam in 
60% yield after silica gel flash column chromatography (CH2Cl2−CH3OH (v/v), from 98:2 to 92:8). 
1
H NMR (CD3CN, 400 MHz, see Table S7) δ 8.02 (bs, 1H), 6.88 (bs, 1H), 6.43 (d, J = 8.4 Hz 1H), 
6.37 (d, J = 7.0 Hz, 1H), 6.26 (dd, J = 9.7 Hz, 1.8, 1H), 5.92 (d, J = 10.2 Hz, 1H), 5.73 (d, J = 10.3 
Hz, 1H), 5.53 (dd, J = 6.9 Hz, 4.8 Hz, 1H), 5.44 (d, J = 10.3, 1H), 5.22 (d, J = 10.0 Hz, 1H), 3.99-
3.92 (m, 1H), 3.89-3.82 (m, 1H), 3.75-3.47 (m , 8H), 3.32 (dt, J = 10.3 Hz, 4.9, 1H), 3.20 (dd, J = 
12.4 Hz, 6.8 Hz, 2H), 3.08 – 3.01 (m, 1H), 2.71 (d, J = 4.7 Hz, 3H), 2.62 – 2.50 (m, 1H), 2.45-2.25 
(m, 5H), 1.87-1.80 (m, 1H), 1.73-1.65 (m, 7H), 1.63-1.56 (m, 1H), 1.49 (s, 9H), 1.42-1.31 (m, 1H), 
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1.25-1.13 (m+d, d, J = 6.7 Hz, 5H), 1.03-0.86 (m, 30H); 
13
C NMR (75 MHz, CD3CN) δ 174.4, 
160.3, 160.2, 159.5, 159.3, 158.0, 155.0, 79.3, 56.4, 53.7, 50.3, 49.0, 47.7, 47.1, 46.0, 46.0, 45.8, 
43.6, 43.1, 42.8, 42.6, 41.6, 31.6, 30.9, 30.6, 27.9, 25.3, 25.1, 24.8, 22.6, 22.6, 21.8, 20.9, 19.1, 
19.0, 18.0, 17.9, 17.5, 17.4, 10.7. HRMS (ESI-TOF) m/z: [M]
+
 Calcd for C44H90N13O7 912.7086; 
Found 912.7078. C18 RP-HPLC (10−100% B in 10 min then 100% B for 3 min): tR = 9.23 min. 
Guanidinylation reaction with 0.5M NH3 in 1,4-dioxane: General procedure VI. S-methylated 
oligomer intermediate (0.34 mmol) was dissolved in CH3CN (10 mL). The mixture was heated to 
40-45°C and the solution of 0.5M ammonia in 1,4-dioxane (20 equiv., 13.6 mL) was added. The 
flask was closed tightly with septum. The monitoring of the reaction was followed by RP-HPLC. 
The reaction was stopped when no further progress was observed.  
Compound 16. 16 was obtained from 2b after 90 hours according to the general procedures III and 
VI (conversion 70% for the guanidylation step, 45 equiv. of 0.5 M NH3 in 1,4-dioxane) as a creamy 
solid with 55% yield after silica gel flash column chromatography (CH2Cl2−CH3OH (v/v), from 
97:3 to 92:8). 
1
H NMR (CD3CN, 300 MHz) δ 7.30 (bs, 2H), 7.08 (bs, 2H), 6.96 (bs, 1H), 5.65 (bs, 
1H), 5.53 (bd, J = 10.3 Hz, 1H), 5.46 (bd, J = 9.3 Hz, 1H), 5.39 (d, J = 9.8 Hz, 1H), 5.20 (d, J = 
10.2 Hz, 1H), 4.06 – 3.96 (m, 1H), 3.81-3.71 (m, 1H), 3.64-3.50 (m, 3H), 3.42-3.31 (m, 2H), 
2.72+2.83-2.65 (d + bm, J = 4.7 Hz, 3H+1H), 2.59-2.22 (m, 4H), 1.76-1.57 (m, 5H), 1.47 (s, 9H), 
1.41-1.36 (m, 2H), 1.28-1.18 (m, 2H), 1.07 (d, J = 6.7 Hz, 3H), 0.94-0.87 (m, 18H); 
13
C NMR 
(CD3OD, 125 MHz with cryoprobe) δ 176.1, 161.4, 161.0, 159.2, 158.0, 80.3, 56.9, 56.4, 51.3, 
49.9, 46.6, 45.9, 45.1, 44.7, 42.5, 33.3, 32.1, 31.8, 28.9, 26.4, 26.2, 26.2, 23.5, 23.5, 22.6, 22.2, 
20.2, 18.8, 18.6. HRMS (ESI-TOF) m/z: [M]
+
 Calcd for C31H64N9O5 642.5030; Found 642.5049. 
C18 RP-HPLC (45−70% B in 25 min): tR = 13.71 min. 
32 
 
Compound 18. 18 was obtained from 4 after 24h according to the procedures III and VI 
(conversion 98% for the guanidylation step, 20 equiv. of 0.5 M NH3 in 1,4-dioxane). The crude 
material was purified by silica gel flash column chromatography (CH2Cl2−CH3OH (v/v), from 95:5 
to 94:6), to give 18 a yellowish foam in 92% yield. 
1
H NMR (CD3CN, 400 MHz) δ 7.22 (b, 2H), 
7.06 (bs, 1H), 6.62 (d, J = 6.7 Hz, 1H), 6.31 (dd, J = 9.6 Hz, 2.1, 1H), 6.18 (d, J = 10.7 Hz, 1H), 
5.82-5.78 (2xd, 2H), 5.71 (dd, J = 9.4 Hz, 3.0, 1H), 5.54 (dd, J = 6.8 Hz, 4.9 Hz, 1H), 5.43 (d, J = 
10.3 Hz, 1H), 5.24 (d, J = 10.0 Hz, 1H), 4.05 (bp, 1H), 3.86-3.75 (m, 2H), 3.65-3.38 (m, 9H), 2.69-
2.63 (m+d, J = 4.7 Hz, 4H), 2.54 (ddd, J = 14.2 Hz, 11.2 Hz, 4.7, 1H), 2.47-2.42 (bp, 1H), 2.37-
2.23 (m, 4H), 1.76-1.66 (m, 6H), 1.46 (s, 9H), 1.36 (t, J = 6.5 Hz, 2H), 1.17 (t, J = 7.2 Hz, 2H), 
1.03 (t, J = 7.1 Hz, 7H), 0.93-0.82 (m, 24H); 
13
C NMR (75 MHz, CD3CN) δ 174.2, 160.7, 160.1, 
159.4, 159.3, 158.0, 157.0, 79.4, 56.5, 54.8, 50.0, 48.0, 47.7, 46.9, 46.0, 45.9, 43.9, 43.6, 43.2, 42.6, 
41.2, 32.3, 30.7, 30.6, 30.4, 27.9, 25.4, 25.0, 24.8, 22.4, 22.3, 21.6, 21.1, 19.2, 19.1, 18.0, 17.9, 
17.4. HRMS (ESI-TOF) m/z: [M]
+
 Calcd for C41H84N13O7 870.6617; Found 870.6591. C18 RP-
HPLC (10−100% B in 10 min then 100% B for 3 min): tR = 9.11 min. 
Solid phase synthesis of resin-bound oligo(thio)urea 20R. 20R was synthesized with BB3 
building blocks according to the recently reported solid phase oligo(thio)urea synthesis procedure 
by locally using N-Fmoc isothiocyanate building block BB4 and azide Trp-type activated monomer 
BB5 under microwave irradiation with the azide strategy on a 50 µmol scale, starting from 
NovaPeg Rink Amide resin (111 mg, 0.45 mmol/g).
37
 Coupling of N-Fmoc--Lys-OH (1.5 equiv. 
relative to the resin loading, 1.5 mmol, 45 mg) was performed in DMF (3 mL) in presence of 
DIPEA (3.0 equiv.) and BOP (3.0 equiv.) under microwave irradiation (50 W, 50 °C, ramp time 5 
min, hold time 30 min). This coupling step was repeated once. Fmoc removal was performed with a 
solution of piperidine in DMF (2:8, v/v, 1 mL), three times 20 min.  
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Compound 20. 20 was obtained from of resin-bound 20R (16 µmol) by performing cleavage of the 
resin in TFA/TIS/H2O solvent mixture (95:2.5:2.5, v/v/v, 2.5 mL). After cold Et2O precipitation, 
the crude material was purified by semi-preparative RP-HPLC (10-45% of B in 20 min at 4 
mL·min
-1
) to furnish 3.9 mg of pure 20 in 17 % yield. 
1
H NMR (CD3OH, 400 MHz, see Table S8); 
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C64H113N21O8S 1336.8880; Found 1336.8904. RP-HPLC 
(10−100% B in 10 min): tR = 6.04 min.  
Solid phase synthesis of resin-bound 21R. Resin bound oligo(thio)urea 20R (26 µmol) wasengaged 
in methylation activation with CH3I (10.0 equiv. relative to resin loading) in DMF (0.5 mL) under 
microwave irradiation (40°C, 20 W, 30 min). The resin was successively washed with DMF (3  3 
mL) and DCM (3  3 mL). This alkylation step was repeated three times with the same washings 
between each activation.  
Solid phase synthesis of resin-bound 22R. The S-methylated resin-bound oligomer 21R was 
washed with anhydrous THF (3  3 mL), then transferred in a sealed reactor. Anhydrous THF (5 
mL) was added and ammonia gas was bubbled into the reactor for 30 min. The reactor was then 
sealed and stirred for 48 hours at 50 °C.  
Compound 22. 22 was obtained from resin-bound 22R by performing cleavage of the resin in 
TFA/TIS/H2O solvent mixture (95:2.5:2.5, v/v/v, 2.5 mL). After cold Et2O precipitation, the crude 
material was purified by semi-preparative RP-HPLC (15-41% of B in 20 min at 4 mL.min
-1
) to 
furnish 6 mg of pure 22 in 17% yield. 
1
H NMR (CD3OH, 400 MHz, see Table S9); HRMS (ESI-
TOF) m/z: [M]+ Calcd for C64H115N22O8 1319.9268; Found 1319.9262. RP-HPLC (10−100% B in 10 
min): tR = 5.35 min. 
Circular dichroism 
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Circular dichroism (CD) experiments were performed on a Jasco J-815 spectrometer. Data are 
expressed in terms of the total molar ellipticity [deg.cm
2
.dmol
-1
]. CD spectra of the oligomers (0.2 
mM) were acquired in spectrograde trifluoroethanol between 180 and 260 nm by using a 
rectangular quartz cell with a path length of 1 mm. To reduce the signal-to-noise ratio all spectra 
were recorded on an average of four consecutive scans.  
Crystallographic data 
See the supporting information for details. CCDC-1563646 and CCDC-1563645 contain the 
supplementary crystallographic data for this paper. These data can be obtained free of charge from 
The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
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